Recombinant Human MIA protein (rFc Tag)

Species

Human

Purity

>85 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2876

Overview

Product Information

Print datasheet

Validation Data Gallery

Purity of Recombinant Human MIA was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

-/ -

Cat No. Eg2876

Freight/Packing: -

Country/Region

Size

Quantity

Please visit your regions distributor:

Request bulk or custom quote

Product Information

Purity	>85 %, SDS-PAGE
Endotoxin	<0.1 EU/μg protein, LAL method
Activity	Not tested
Expression	HEK293-derived Human MIA protein Gly25-Gln131 (Accession# Q16674-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID	8190
Accession	Q16674-1
PredictedSize	38.1 kDa
SDS-PAGE	37-42 kDa, reducing (R) conditions
Formulation	Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution	Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions	It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. Until expiry date, -20℃ to -80℃ as lyophilized proteins. 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Melanoma Inhibitory Activity (MIA) is a small secreted protein that interacts with extracellular matrix proteins. Initially identified as an inhibitor of in vitro growth of malignant melanoma cells, it has been found to play a role in the metastatic behavior of various cancers, including melanoma and pancreatic cancer. MIA is overexpressed in these cancers and can promote tumor cell invasiveness. It adopts an SH3 domain-like fold and interacts with fibronectin, potentially detaching cells from the extracellular matrix. MIA is also a clinically valuable serum marker for malignant melanoma.

References:

1.Schmidt, Jennifer, and Anja-Katrin Bosserhoff. International journal of cancer vol. 125,7 (2009): 1587-94. 2.El Fitori, Jamael et al. Cancer cell international vol. 5,1 (2005): 3. 3.Schmidt, Jennifer et al. Histology and histopathology vol. 28,4 (2013): 421-6. 4.Bosserhoff, Anja-Katrin. Pigment cell research vol. 18,6 (2005): 411-6.